Viking Therapeutics Q2 net loss widens, misses expectations

Reuters

24 Jul

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens, misses expectations

Overview

Viking Therapeutics Q2 net loss of $65.6 mln misses analyst expectations
EPS for Q2 misses estimates due to higher R&D and admin expenses
Company maintains strong cash position of $808 mln to support clinical trials

Outlook

Company expects top-line results from VENTURE-Oral study in 2H25
Viking plans IND submission for DACRA program in 4Q25
Amylin program IND filing expected in Q4 2025

Result Drivers

PHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetes
PHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trial

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 EPS	Miss	-$0.58	-$0.45 (19 Analysts)
Q2 Net Income	Miss	-$65.56 mln	-$51.60 mln (16 Analysts)
Q2 Income from Operations	Miss	-$74.57 mln	-$59.10 mln (15 Analysts)
Q2 Operating Expenses		$74.57 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10

Press Release: ID:nPn9SCNZpa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553228669"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553228669\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553228669?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553228669","market":"us","top_or_hot":-1,"title":"Viking Therapeutics Q2 net loss widens, misses expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, misses expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Viking Therapeutics Q2 net loss of $65.6 mln misses analyst expectations</p></li><li><p>EPS for Q2 misses estimates due to higher R&amp;D and admin expenses</p></li><li><p>Company maintains strong cash position of $808 mln to support clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects top-line results from VENTURE-Oral study in 2H25</p></li><li><p>Viking plans IND submission for DACRA program in 4Q25</p></li><li><p>Amylin program IND filing expected in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetes</p></li><li><p>PHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trial</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-$0.58</p></td><td><p>-$0.45 (19 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$65.56 mln</p></td><td><p>-$51.60 mln (16 Analysts)</p></td></tr><tr><td><p>Q2 Income from Operations</p></td><td><p>Miss</p></td><td><p>-$74.57 mln</p></td><td><p>-$59.10 mln (15 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$74.57 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10</p></li></ul><p>Press Release: <span>ID:nPn9SCNZpa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Q2 net loss widens, misses expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Q2 net loss widens, misses expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 04:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens, misses expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Viking Therapeutics Q2 net loss of $65.6 mln misses analyst expectations</p></li><li><p>EPS for Q2 misses estimates due to higher R&amp;D and admin expenses</p></li><li><p>Company maintains strong cash position of $808 mln to support clinical trials</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects top-line results from VENTURE-Oral study in 2H25</p></li><li><p>Viking plans IND submission for DACRA program in 4Q25</p></li><li><p>Amylin program IND filing expected in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetes</p></li><li><p>PHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trial</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-$0.58</p></td><td><p>-$0.45 (19 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$65.56 mln</p></td><td><p>-$51.60 mln (16 Analysts)</p></td></tr><tr><td><p>Q2 Income from Operations</p></td><td><p>Miss</p></td><td><p>-$74.57 mln</p></td><td><p>-$59.10 mln (15 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$74.57 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p><a href=\"https://laohu8.com/S/WSCO\">Wall Street</a>'s median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10</p></li></ul><p>Press Release: <span>ID:nPn9SCNZpa</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nPLXBE4039:1","article_id":"2553228669","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553228669","pubTimestamp":1753302908,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viking Therapeutics Q2 net loss widens, misses expectationsOverviewViking Therapeutics Q2 net loss of $65.6 mln misses analyst expectationsEPS for Q2 misses estimates due to higher R&D and admin expen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","VKTX":"Viking Therapeutics, Inc.","BK4599":"减肥药"},"translate_title":"Viking Therapeutics第二季度净亏损扩大，低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics Q2 net loss widens, misses expectationsOverviewViking Therapeutics Q2 net loss of $65.6 mln misses analyst expectationsEPS for Q2 misses estimates due to higher R&D and admin expensesCompany maintains strong cash position of $808 mln to support clinical trialsOutlookCompany expects top-line results from VENTURE-Oral study in 2H25Viking plans IND submission for DACRA program in 4Q25Amylin program IND filing expected in Q4 2025Result DriversPHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetesPHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trialKey DetailsMetricBeat/MissActualConsensus EstimateQ2 EPSMiss-$0.58-$0.45 (19 Analysts)Q2 Net IncomeMiss-$65.56 mln-$51.60 mln (16 Analysts)Q2 Income from OperationsMiss-$74.57 mln-$59.10 mln (15 Analysts)Q2 Operating Expenses$74.57 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 17 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10Press Release: ID:nPn9SCNZpa(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}